Sint-Lambrechts-Woluwe

• Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101) Ended recruitment
  2023-506794-35-00 3 2022-04-01 Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended recruitment
  2023-503640-14-00 5 2022-02-17 Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
• A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with I … Ended recruitment
  2024-515617-18-00 1 2022-02-14 Advanced clear cell renal cell carcinoma (ccRCC), non-clear cell renal
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the b … Ended recruitment
  2023-504884-17-00 5 2022-02-04 Proteinuria
• Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 Expression Ended recruitment
  2024-510655-36-00 7 2022-02-01 Advanced Malignancies Associated with EphA2 Expression
• A long term Investigation of the Safety and Efficacy of Odevixibat in Patients with Alagille syndrome Ended recruitment
  2023-509028-17-00 5 2022-01-06 Alagille Syndrome
• VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif … Ended recruitment
  2023-507286-25-00 4 2021-12-23 Diffuse Large B-Cell Lymphoma
• Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL tri … Ended recruitment
  2023-508242-18-00 6 2021-12-21 Crohn's disease
• A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Year … Ended recruitment
  2022-501067-40-00 5 2021-11-30 Moderately to Severely Active Ulcerative Colitis
• A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance … Ended recruitment
  2023-509133-39-00 5 2021-11-29 Hormone receptor positive, HER2-negative advanced breast cancer
• A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr … Ended recruitment
  2023-508248-23-00 5 2021-11-26 Non-alcoholic steatohepatitis (NASH)
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506257-37-00 5 2021-10-29 Active Psoriatic Arthritis
• A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Ended recruitment
  2023-508723-12-00 5 2021-09-27 gastroenteropancreatic neuroendocrine tumors
• Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended recruitment
  2024-510809-28-00 5 2021-09-27 Metastatic Castration-sensitive Prostate Cancer
• A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combina … Ended recruitment
  2023-510307-22-00 1 2021-09-24 Advanced head and neck cancer
• An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic … Ended recruitment
  2024-514905-79-00 9 2021-09-17 Metastatic pancreatic ductal adenocarcinoma
• The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec … Ended recruitment
  2024-512038-13-00 5 2021-09-16 Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
• An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn's disease previously included in the loss … Ended recruitment
  2024-514326-23-00 11 2021-09-10 Crohn's disease
• Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended recruitment
  2023-503905-12-00 4 2021-08-20 Liver cancer; Colon cancer; Pancreatic cancer; Bile Duct or Gallbladde
• Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A … Ended recruitment
  2023-507963-20-00 5 2021-08-19 Metastatic Gastric Adenocarcinoma
• A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended recruitment
  2022-502100-70-00 10 2021-06-23 Participants with Microsatellite Instability-High (MSI-H) or Mismatch
• PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therap … Ended recruitment
  2023-507772-50-00 5 2021-06-16 PSMA-positive metastatic castration-resistant prostate cancer
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello- … Ended recruitment
  2023-504997-39-00 5 2021-06-14 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2

Showing 409–432 of 635 trials